US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
AU760020B2
(en)
*
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
SK3842001A3
(en)
*
|
1998-09-18 |
2002-04-04 |
Basf Ag |
Pyrrolopyrimidines as protein kinase inhibitors (revised)
|
US6265403B1
(en)
*
|
1999-01-20 |
2001-07-24 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
AU7491400A
(en)
*
|
1999-09-17 |
2001-04-17 |
Abbott Gmbh & Co. Kg |
Kinase inhibitors as therapeutic agents
|
IL148718A0
(en)
|
1999-09-17 |
2002-09-12 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidines as therapeutic agents
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
WO2001072751A1
(fr)
*
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
|
MXPA02009543A
(es)
*
|
2000-03-29 |
2005-08-26 |
Abbott Gmbh & Co Kg |
Metodo para identificar inhibidores de tie-2.
|
US7369946B2
(en)
|
2000-03-29 |
2008-05-06 |
Abbott Gmbh & Co. Kg |
Method of identifying inhibitors of Tie-2
|
KR100403860B1
(ko)
*
|
2000-12-27 |
2003-11-01 |
엘지전자 주식회사 |
차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
AR035885A1
(es)
*
|
2001-05-14 |
2004-07-21 |
Novartis Ag |
Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
|
MXPA03011998A
(es)
*
|
2001-06-23 |
2005-07-01 |
Aventis Pharma Inc |
Pirrolopirimidinas como inhibidores de protein cinasa.
|
DE60227709D1
(de)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
|
CA2452368A1
(fr)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
|
DE60216281T2
(de)
|
2001-06-29 |
2007-07-05 |
Ab Science |
Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
|
US20040266771A1
(en)
*
|
2001-06-29 |
2004-12-30 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating bone loss
|
PT1401415E
(pt)
|
2001-06-29 |
2006-09-29 |
Ab Science |
Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias
|
ATE343415T1
(de)
|
2001-06-29 |
2006-11-15 |
Ab Science |
Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
|
WO2003002107A2
(fr)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
|
GB0121033D0
(en)
*
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
US7427623B2
(en)
|
2001-09-11 |
2008-09-23 |
Smithkline Beecham Corporation |
4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
KR20050067383A
(ko)
|
2002-08-06 |
2005-07-01 |
아스트라제네카 아베 |
Tie2(tek) 활성을 갖는 축합 피리딘 및 피리미딘
|
UA80171C2
(en)
*
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
WO2004100868A2
(fr)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Procede servant a traiter le rejet d'un transplant
|
US7592352B2
(en)
*
|
2003-05-06 |
2009-09-22 |
Smithkline Beecham Corporation |
Substituted thieno and furo-pyridines
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
MXPA06005578A
(es)
*
|
2003-11-17 |
2006-08-11 |
Pfizer Prod Inc |
Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
|
CA2553724A1
(fr)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Utilisation d'aminobenzoxazoles comme agents therapeutiques
|
GB0403606D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
JP4842929B2
(ja)
*
|
2004-05-27 |
2011-12-21 |
ファイザー・プロダクツ・インク |
癌治療に有用なピロロピリミジン誘導体
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
EP1871773A1
(fr)
*
|
2005-03-17 |
2008-01-02 |
Novartis AG |
N-[3-(1-amin0-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yle)-phenyl] benzamides utilises en tant qu'inhibiteurs de tyrosine/threonine kinase, en particulier la b-raf kinase
|
JP2009513571A
(ja)
*
|
2005-09-30 |
2009-04-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ヤヌスキナーゼ阻害剤として有用なデアザプリン
|
CN102936250B
(zh)
*
|
2005-11-17 |
2014-07-09 |
Osi医药有限责任公司 |
稠合双环mTOR抑制剂
|
CA2631664C
(fr)
*
|
2005-12-08 |
2012-05-08 |
Abbott Laboratories |
Inhibiteurs de proteines kinases
|
EP1983971A4
(fr)
*
|
2006-01-25 |
2010-11-24 |
Synta Pharmaceuticals Corp |
Composés aromatiques substitués destinés à des utilisations contre des inflammations et des troubles immunitaires
|
TW200738725A
(en)
*
|
2006-01-25 |
2007-10-16 |
Osi Pharm Inc |
Unsaturated mTOR inhibitors
|
CA2647391C
(fr)
*
|
2006-04-04 |
2015-12-29 |
The Regents Of The University Of California |
Antagonistes de la kinase
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
US7514444B2
(en)
|
2006-09-22 |
2009-04-07 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
EP1969934A1
(fr)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
Phénoxyphénylamidine substituée par 4 cycloalkyl ou 4 aryl et son utilisation en tant que fongicide
|
IL295053A
(en)
*
|
2007-03-28 |
2022-09-01 |
Pharmacyclics Llc |
Broton tyrosine kinase inhibitors
|
US20120101113A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
MX2010007419A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2252293B1
(fr)
|
2008-03-14 |
2018-06-27 |
Intellikine, LLC |
Inhibiteurs de kinases, et procédés d utilisation associés
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
EA018144B1
(ru)
*
|
2008-03-19 |
2013-05-30 |
Оси Фармасьютикалз, Инк. |
СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
|
WO2010006072A2
(fr)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Modulateurs de mtor et leurs utilisations
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
US8604032B2
(en)
|
2010-05-21 |
2013-12-10 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
MY191929A
(en)
|
2010-06-03 |
2022-07-18 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
EP2637669A4
(fr)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Composés hétérocycliques et utilisations de ceux-ci
|
JP2014501790A
(ja)
|
2011-01-10 |
2014-01-23 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
イソキノリノンの調製方法及びイソキノリノンの固体形態
|
FR2970967B1
(fr)
*
|
2011-01-27 |
2013-02-15 |
Pf Medicament |
Derives de type azaindazole ou diazaindazole comme medicament
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
EA201391239A1
(ru)
*
|
2011-04-05 |
2014-03-31 |
Пфайзер Лимитед |
Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
|
US9138436B2
(en)
|
2011-07-13 |
2015-09-22 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
KR20140075693A
(ko)
|
2011-08-29 |
2014-06-19 |
인피니티 파마슈티칼스, 인코포레이티드 |
헤테로사이클릭 화합물 및 그의 용도
|
AU2012341028C1
(en)
|
2011-09-02 |
2017-10-19 |
Mount Sinai School Of Medicine |
Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2844251B1
(fr)
|
2012-05-03 |
2018-08-01 |
Saint Louis College of Pharmacy |
Compositions et procédés pour augmenter des peptides neurotrophiques
|
BR112014030424A8
(pt)
|
2012-06-04 |
2017-07-11 |
Pharmacyclics Inc |
Formas cristalinas de um inibidor de quinase de tirosina de bruton
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
EP2689778A1
(fr)
*
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
|
EP2900673A4
(fr)
|
2012-09-26 |
2016-10-19 |
Univ California |
Modulation de ire1
|
AU2013344656A1
(en)
|
2012-11-15 |
2015-06-04 |
Pharmacyclics Llc |
Pyrrolopyrimidine compounds as kinase inhibitors
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
CN103333096A
(zh)
*
|
2013-06-25 |
2013-10-02 |
苏州大学 |
一种化学选择性制备多功能吡咯衍生物的新方法
|
US9624224B2
(en)
|
2013-09-30 |
2017-04-18 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
WO2015051241A1
(fr)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
DK3052485T3
(da)
|
2013-10-04 |
2021-10-11 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser og anvendelser deraf
|
DK3119397T3
(da)
|
2014-03-19 |
2022-03-28 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
EP3174539A4
(fr)
|
2014-08-01 |
2017-12-13 |
Pharmacyclics, LLC |
Inhibiteurs de la tyrosine kinase de bruton
|
SG11201700849XA
(en)
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
KR20170122220A
(ko)
|
2015-03-03 |
2017-11-03 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나제 저해제의 약제학적 제제
|
EP3334430A4
(fr)
*
|
2015-08-13 |
2019-02-06 |
San Diego State University Foundation |
Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase
|
JP6980649B2
(ja)
|
2015-09-14 |
2021-12-15 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SI3472165T1
(sl)
|
2016-06-21 |
2024-02-29 |
Nerviano Medical Sciences S.R.L., |
N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz
|
UA125216C2
(uk)
|
2016-06-24 |
2022-02-02 |
Інфініті Фармасьютікалз, Інк. |
Комбінована терапія
|
EP3612519B1
(fr)
|
2017-04-18 |
2021-12-01 |
Eli Lilly and Company |
Composés de phényl-2-hydroxy-acétylamino-2-méthyl-phényle
|
KR20210047320A
(ko)
*
|
2018-08-22 |
2021-04-29 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
피롤로-아미노-피리다지논 화합물 및 이의 중간체의 제조 방법
|
KR20220021462A
(ko)
*
|
2019-04-10 |
2022-02-22 |
셀레스티아 바이오테크 아게 |
Notch 신호 전달 경로의 억제제 및 암의 치료에서 이의 용도
|
KR20220007889A
(ko)
*
|
2019-05-13 |
2022-01-19 |
릴레이 테라퓨틱스, 인크. |
Fgfr 저해제 및 이의 사용 방법
|
CN110483523B
(zh)
*
|
2019-08-27 |
2022-11-22 |
药雅科技(上海)有限公司 |
一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
AU2020336975A1
(en)
*
|
2019-08-29 |
2022-03-31 |
Hibercell, Inc. |
Perk inhibiting pyrrolopyrimidine compounds
|
WO2021038540A1
(fr)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
TW202233625A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商傳達治療有限公司 |
Fgfr抑制劑及其製造及使用方法
|
PE20231311A1
(es)
|
2020-11-18 |
2023-08-24 |
Deciphera Pharmaceuticals Llc |
Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
|
WO2023046117A1
(fr)
*
|
2021-09-23 |
2023-03-30 |
3H Pharmaceuticals Co., Ltd. |
Inhibiteurs de fgfr et leurs procédés d'utilisation
|
WO2023104035A1
(fr)
*
|
2021-12-06 |
2023-06-15 |
英矽智能科技(上海)有限公司 |
Composé hétérocyclique monocyclique ou bicyclique substitué, son procédé de préparation et son utilisation médicale
|
WO2023202625A1
(fr)
*
|
2022-04-20 |
2023-10-26 |
深圳福沃药业有限公司 |
Inhibiteur de fgfr2 et son procédé d'utilisation
|